系统性硬化症亚临床间质性肺病的筛查与管理:一项国际调查
该国际调查通过电子问卷向风湿科医生、呼吸科医生及硬皮病/间质性肺病专家发放,共198人应答。结果显示59%的受访者对所有新诊断SSc患者常规开具高分辨率CT,48%的受访者不治疗亚临床SSc-ILD,且风湿科医生与呼吸科医生在治疗决策上存在显著异质性,MMF为首选一线药物。
要点
- 59%的受访者对所有新诊断SSc患者常规开具高分辨率CT,但地区差异明显。
- 48%的受访者不治疗亚临床SSc-ILD,52%会治疗或考虑治疗。
- MMF是治疗亚临床SSc-ILD的首选一线药物。
核心结论
- 该国际调查揭示了SSc-ILD筛查方面存在重要的地区差异,以及风湿科医生与呼吸科医生在亚临床SSc-ILD治疗上存在显著异质性。
- 原文结论指出需要高质量研究来制定循证指南并统一亚临床SSc-ILD的识别与治疗方法。
研究设计与样本
- 研究为国际电子REDCap问卷调查,发放对象包括611名普通风湿科医生、348名国家和国际SSc专家、285名普通呼吸科医生和57名ILD专家。
- 共198名参与者应答,包括135名(68%)风湿科医生和54名(27%)呼吸科医生。
主要发现
- 超过半数(59%)的受访者对所有新诊断SSc患者常规开具高分辨率CT。
- 常规开具高分辨率CT的做法在欧洲为83%、美国为68%、亚洲为73%、拉丁美洲为100%,高于加拿大(40%)和澳大利亚(40%)。
- 近半数(48%)的受访者不治疗亚临床SSc-ILD,而52%会治疗或考虑治疗。
- 至少70%的受访者在弥漫型SSc、抗拓扑异构酶I自身抗体阳性、病程短于18个月、磨玻璃影、氧饱和度下降或影像学/肺功能检查显示ILD显著进展的情况下可能治疗亚临床ILD。
- 大多数(67%)呼吸科医生不治疗亚临床ILD;MMF是治疗亚临床SSc-ILD的首选一线药物。
关键数值与推荐
- 59%的受访者对所有新诊断SSc患者常规开具高分辨率CT。
- 48%的受访者不治疗亚临床SSc-ILD,52%会治疗或考虑治疗。
- 至少70%的受访者在弥漫型SSc、抗拓扑异构酶I自身抗体阳性、病程短于18个月、磨玻璃影、氧饱和度下降或影像学/肺功能检查显示ILD显著进展的情况下可能治疗亚临床ILD。
- 67%的呼吸科医生不治疗亚临床ILD。
- MMF是治疗亚临床SSc-ILD的首选一线药物。
临床怎么用
- 原文未据此给出推荐。
- 原文结论指出需要高质量研究来制定循证指南并统一亚临床SSc-ILD的识别与治疗方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interstitial lung disease (ILD) is the leading cause of mortality in SSc. Experts now recommend high-resolution CT (HRCT) screening in all SSc patients and treatment of subclinical ILD in SSc patients with high-risk phenotypes. We undertook an international survey to understand current screening and treatment practices in subclinical SSc-ILD. METHODS: An electronic REDCap survey was distributed to 611 general rheumatologists, 348 national and international SSc experts, 285 general respirologists and 57 ILD experts. RESULTS: One hundred and ninety-eight participants responded to the survey, including 135 (68%) rheumatologists and 54 (27%) respirologists. Over half (59%) of respondents routinely ordered HRCTs in all newly diagnosed SSc patients, although this practice was more common in Europe (83%), the USA (68%), Asia (73%) and Latin America (100%) compared with Canada (40%) and Australia (40%). Nearly half (48%) of respondents would not treat subclinical SSc-ILD, whereas 52% would treat or consider treatment. At least 70% would likely treat subclinical ILD in the setting of diffuse SSc, anti-topoisomerase-I autoantibodies, disease duration below 18 months, ground-glass opacities, oxygen desaturation, or significant ILD progression on imaging or pulmonary function tests. The majority (67%) of respirologists would not treat subclinical ILD. MMF was the preferred first-line drug for the treatment of subclinical SSc-ILD. CONCLUSION: This international survey highlights important regional variations in SSc-ILD screening and significant heterogeneity among rheumatologists and respirologists in the treatment of subclinical SSc-ILD. High-quality research addressing these questions is needed to produce evidence-based guidelines and harmonize the approach to identification and treatment of subclinical SSc-ILD.
引用
- Hoa S, Baron M, Hudson M, et al. Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey. Rheumatology (Oxford). 2022. PMID: 34918033. doi:10.1093/rheumatology/keab929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。